AstraZeneca China said 13 of its innovative medicines were included in the new version of China’s National Reimbursement Drug List (NRDL) and the commercial insurance innovative drug list, expanding reimbursement and access for oncology, respiratory, immune, renal and rare-disease patients. On the NRDL, two medicines were listed for the first time, five gained new indications, four were renewed and one was reclassified into regular Category B. Separately, one AstraZeneca medicine was newly inclu

AstraZeneca China said 13 of its innovative medicines were included in the new version of China’s National Reimbursement Drug List (NRDL) and the commercial insurance innovative drug list, expanding reimbursement and access for oncology, respiratory, immune, renal and rare-disease patients. On the NRDL, two medicines were listed for the first time, five gained new indications, four were renewed and one was reclassified into regular Category B. Separately, one AstraZeneca medicine was newly included in the commercial insurance innovative drug list.